Exhibit 10.1
ACQUISITION OF ADVANCED GENETIC TECHNOLOGIES, INC.
by
CYTODYN, INC.
AGREEMENT AND PLAN OF ACQUISITION
This Agreement and Plan of Acquisition ("Agreement") is entered into by
and between Advanced Genetic Technologies, Inc., a Florida corporation ("AGTI"),
UTEK CORPORATION, a Delaware corporation ("UTEK"), and CytoDyn, Inc., a Colorado
corporation ("CYDY").
WHEREAS, UTEK owns 100% of the issued and outstanding shares of common
stock of AGTI ("AGTI Shares");
WHEREAS, before the Closing Date, AGTI will acquire the license for the
fields of use as described in the License Agreement which is attached hereto as
part of Exhibit A and made a part of this Agreement (License Agreement) and the
rights to develop and market a patented and proprietary technology for the
fields of uses specified in the License Agreement (Technology);
WHEREAS, the parties desire to provide for the terms and conditions upon
which AGTI will be acquired by CYDY in a stock-for-stock exchange
("Acquisition") in accordance with the respective corporation laws of their
state, upon consummation of which all AGTI Shares will be owned by CYDY, and all
or a portion of the issued and outstanding AGTI Shares will be exchanged for
convertible preferred stock of CYDY with terms and conditions as set forth more
fully in this Agreement; and
WHEREAS, for federal income tax purposes, it is intended that the
Acquisition qualifies within the meaning of Section 368 (a)(1)(B) of the
Internal Revenue Code of 1986, as amended ("Code").
NOW, THEREFORE, in consideration of the premises and for other good and
valuable consideration, the receipt, adequacy and sufficiency of which are by
this Agreement acknowledged, the parties agree as follows:
ARTICLE 1
THE STOCK-FOR-STOCK ACQUISITION
1.01 The Acquisition
(a) Acquisition Agreement. Subject to the terms and conditions of
this Agreement, at the Effective Date, as defined below, all AGTI Shares shall
be acquired from UTEK by CYDY in accordance with the respective corporation laws
of their states and the provisions of this Agreement and the separate corporate
existence of AGTI, as a wholly-owned subsidiary of CYDY, shall continue after
the closing.
(b) Effective Date. The Acquisition shall become effective
("Effective Date") upon the execution of this Agreement and closing of the
transaction.
1.02 Consideration.
In the amount of: $1,300,000 based on Convertible Preferred stock as has
been approved and authorized by the board of directors of CYDY:
Page 1 of 17
a) On the date of closing ("the Effective Date") CytoDyn, Inc. (CYDY)
shall acquire all 1,000 Shares of common stock of Advanced Genetic
Technologies, Inc, which represent all of the issued and
outstanding Shares at the date of closing, and in exchange, CYDY
shall issue to UTEK 100,000 shares of convertible preferred stock
(as described in Exhibit D of the Acquisition Agreement).
b) At any time after Twelve (12) months and before 36 months from the
date of closing, UTEK shall have the option right to convert part
or all its convertible preferred stock to restricted common stock
("Conversion Shares") of CYDY, to be adjusted to equal the total
amount of $1,300,000 based on the previous 10 day average closing
bid price on the day of conversion. For example, if on the date of
conversion of all shares to common, if the 10 day average closing
bid price is $1.00, then UTEK shall receive 1,300,000 shares of
common stock in CYDY. The common stock that UTEK receives shall be
delivered to UTEK within 30 days of the conversion.
c) At CytoDyn's next scheduled shareholders meeting following the
date of executing this Agreement, the shareholders will be asked
to approve and authorize a minimum of 1,300,000 shares of CYDY
stock to be given to CYDY's transfer agent to comply with the
Irrevocable Transfer Agent Instructions (Section (1.02-d below),
to the Transfer Agent, attached and made part of this Agreement,
to hold for the purpose of converting the preferred convertible
shares held by UTEK. These newly authorized shares shall be
delivered to the transfer agent within 30 days of this
authorization by the shareholders.
d) The IRREVOCABLE TRANSFER AGENT INSTRUCTIONS, attached hereto,
shall be agreed to and shall instruct the Transfer Agent to
effectuate UTEK'S option to convert said shares.
e) The return yield on the convertible preferred stock shall be 5%
compounded quarterly, paid in cash or in-kind, and will be
required to be repaid at the time of conversion by CYDY to UTEK.
f) Exchange of Stock. At the Effective Date, by virtue of the
Acquisition, all of the AGTI Shares that are issued and
outstanding at the Effective Date shall be exchanged for 100,000
Convertible Preferred shares of CYDY (CYDY Shares, as described in
Exhibit D) as follows:
To: CYDY Convertible Preferred Shares
--- ---------------------------------
UTEK Corporation 100,000
1.03 Effect of Acquisition.
(a) Rights in AGTI Cease. At and after the Effective Date, the
holder of each certificate of common stock of AGTI shall cease to have any
rights as a shareholder of AGTI.
(b) Closure of AGTI Shares Records. From and after the Effective
Date, the stock transfer books of AGTI shall be closed, and there shall be no
further registration of stock transfers on the records of AGTI. 1.04 Closing.
Subject to the terms and conditions of this Agreement, the Closing of the
Page 2 of 17
Acquisition shall be the date of the last executed signature affixed to this
Agreement, but in no event later than January 26, 2007.
ARTICLE 2
REPRESENTATIONS AND WARRANTIES
2.01 Representations and Warranties of UTEK and AGTI. UTEK and AGTI
jointly and severally represent and warrant to CYDY that the facts set forth
below are true and correct:
(a) Organization. AGTI and UTEK are corporations duly organized,
validly existing and in good standing under the laws of their respective states
of incorporation, and they have the requisite power and authority to conduct
their business and consummate the transactions contemplated by this Agreement.
True, correct and complete copies of the articles of incorporation, bylaws and
all corporate minutes of AGTI have been provided to CYDY and such documents are
presently in effect and have not been amended or modified.
(b) Authorization. The execution of this Agreement and the
consummation of the Acquisition and the other transactions contemplated by this
Agreement have been duly authorized by the board of directors and shareholder of
AGTI and the board of directors of UTEK; no other corporate action by the
respective parties is necessary in order to execute, deliver, consummate and
perform their respective obligations hereunder; and AGTI and UTEK have all
requisite corporate and other authority to execute and deliver this Agreement
and consummate the transactions contemplated by this Agreement.
(c) Capitalization. The authorized capital of AGTI consists of
1,000,000 shares of common stock with a par value $.01 per share. At the date of
this Agreement, 1,000 AGTI Shares are issued and outstanding as follows:
Shareholder Number of AGTI Shares
----------- ---------------------
UTEK Corporation 1000
All issued and outstanding AGTI Shares have been duly and validly issued and are
fully paid and non-assessable shares and have not been issued in violation of
any preemptive or other rights of any other person or any applicable laws. AGTI
is not authorized to issue any preferred stock. All dividends on AGTI Shares
which have been declared prior to the date of this Agreement have been paid in
full. There are no outstanding options, warrants, commitments, calls or other
rights or Agreements requiring AGTI to issue any AGTI Shares or securities
convertible, exercisable or exchangeable into AGTI Shares to anyone for any
reason whatsoever. None of the AGTI Shares is subject to any charge, claim,
condition, interest, lien, pledge, option, security interest or other
encumbrance or restriction, including any restriction on use, voting, transfer,
receipt of income or exercise of any other attribute of ownership.
(d) Binding Effect. The execution, delivery, performance and
consummation of this Agreement, the Acquisition and the transactions
contemplated by this Agreement will not violate any obligation to which AGTI or
UTEK is a party and will not create a default under any such obligation or under
any Agreement to which AGTI or UTEK is a party. This Agreement constitutes a
legal, valid and binding obligation of AGTI, enforceable in accordance with its
terms, except as the enforcement may be limited by bankruptcy, insolvency,
moratorium, or similar laws affecting creditor's rights generally and by the
availability of injunctive relief, specific performance or other equitable
remedies.
(e) Litigation Relating to this Agreement. There are no suits,
actions or proceedings pending or, to the best of AGTl's and UTEK's knowledge,
information and belief, threatened, which seek to enjoin the Acquisition or the
Page 3 of 17
transactions contemplated by this Agreement or which, if adversely decided,
would have a materially diverse effect on the business, results of operations,
assets or prospects of AGTI.
(f) No Conflicting Agreements. Neither the execution and delivery
of this Agreement nor the fulfillment of or compliance by AGTI or UTEK with the
terms or provisions of this Agreement nor all other documents or agreements
contemplated by this Agreement and the consummation of the transaction
contemplated by this Agreement will result in a breach of the terms, conditions
or provisions of, or constitute a default under, or result in a violation of,
AGTl's or UTEK's articles of incorporation or bylaws, the Technology, the
License Agreement, the Consulting Agreement, or any agreement, contract,
instrument, order, judgment or decree to which AGTI or UTEK is a party or by
which AGTI or UTEK or any oftheir respective assets is bound, or violate any
provision of any applicable law, rule or regulation or any order, decree, writ
or injunction of any court or government entity which materially affects their
respective assets or businesses.
(g) Consents. No consent from or approval of any court,
governmental entity or any other person is necessary in connection with
execution and delivery of this Agreement by AGTI and UTEK or performance of the
obligations of AGTI and UTEK hereunder or under any other agreement to which
AGTI or UTEK is a party; and the consummation of the transactions contemplated
by this Agreement will not require the approval of any entity or person in order
to prevent the termination of the Technology, the License Agreement, the
Consulting Agreement or any other material right, privilege, license or
agreement relating to AGTI or its assets or business.
(h) Title to Assets. AGTI has or has agreed to enter into the
agreements as listed on Exhibit A attached hereto. These agreements and the
assets shown on the balance sheet of attached Exhibit B are the sole assets of
AGTI. Except as set forth on Schedule 2.01(h), AGTI has good and marketable
title to its assets, free and clear of all liens, claims, charges, mortgages,
options, security agreements and other encumbrances of every kind or nature
whatsoever. On the Closing Date, AGTI will have good and marketable title to its
assets, free and clear of all liens, claims, charges, mortgages, options,
security agreements and other encumbrances of every kind and nature whatsoever.
(i) Intellectual Property
(1) The CBR Institute for Biomedical Research, affiliated
with the Harvard Medical School ("Laboratory") invented and owns the Technology
and has all right, power, authority and ownership with respect to the Inventions
listed in Exhibit A hereto.
(2) The License Agreement between Laboratory and AGTI
covering the Inventions is legal, valid, binding and will be enforceable in
accordance with its terms as contained in Exhibit A.
(3) Except as otherwise set forth in this Agreement, CYDY
acknowledges and understands that AGTI and UTEK make no representations and
provide no assurances that the rights to the Technology and Intellectual
Property contained in the License Agreement do not, and will not in the future,
infringe or otherwise violate the rights of third parties; however, AGTI and
UTEK have no knowledge of pending or threatened claims by, or any basis for any
claims by, any third parties alleging such infringement or other violation, and
(4) Except as otherwise expressly set forth in this
Agreement, AGTI and UTEK make no representations and extend no warranties of any
kind, either express or implied, including, but not limited to warranties of
merchantability, fitness for a particular purpose, non-infringement and validity
of the Intellectual Property.
(j) Liabilities of AGTI. AGTI has no assets (except as set forth
in Section 2.01 (h)), no liabilities or obligations of any kind, character or
description except those listed on the attached schedules and exhibits.
Page 4 of l7
(k) Financial Statements. The unaudited financial statements of
AGTI, including a balance sheet, attached as Exhibit B and made a part of this
Agreement, are, in all respects, complete and correct and present fairly AGTl's
financial position and the results of its operations on the dates and for the
periods shown in this Agreement; provided, however, that interim financial
statements are subject to customary year-end adjustments and accruals that, in
the aggregate, will not have a material adverse effect on the overall financial
condition or results of its operations. AGTI has not engaged in any business not
reflected in its financial statements. There have been no material adverse
changes in the nature of its business, prospects, the value of assets or the
financial condition since the date of its financial statements. There are no,
and on the Closing Date there will be no, outstanding obligations or liabilities
of AGTI except as specifically set forth in the financial statements and the
other attached schedules and exhibits. There is no information known to AGTI or
UTEK that would prevent the financial statements of AGTI from being audited in
accordance with generally accepted accounting principles.
(l) Taxes. All returns, reports, statements and other similar
filings required to be filed by AGTI with respect to any federal, state, local
or foreign taxes, assessments, interests, penalties, deficiencies, fees and
other governmental charges or impositions have been timely filed with the
appropriate governmental agencies in all jurisdictions in which such tax returns
and other related filings are required to be filed; all such tax returns
property reflect all liabilities of AGTI for taxes for the periods, property or
events covered by this Agreement; and all taxes, whether or not reflected on
those tax returns, and all taxes claimed to be due from AGTI by any taxing
authority, have been properly paid, except to the extent reflected on AGTl's
financial statements, where AGTI has contested in good faith by appropriate
proceedings and reserves have been established on its financial statements to
the full extent if the contest is adversely decided against it. AGTI has not
received any notice of assessment or proposed assessment in connection with any
tax returns, nor is AGTI a party to or to the best of its knowledge, expected to
become a party to any pending or threatened action or proceeding, assessment or
collection of taxes. AGTI has not extended or waived the application of any
statute of limitations of any jurisdiction regarding the assessment or
collection of any taxes. There are no tax liens (other than any lien which
arises by operation of law for current taxes not yet due and payable) on any of
its assets. There is no basis for any additional assessment of taxes, interest
or penalties. AGTI has made all deposits required by law to be made with respect
to employees' withholding and other employment taxes, including without
limitation the portion of such deposits relating to taxes imposed upon AGTI.
AGTI is not and has never been a party to any tax-sharing agreements with any
other person or entity.
(m) Absence of Certain Changes or Events. From the date of the
full execution of the Term Sheet until the Closing Date, AGTI has not, and
without the written consent of CYDY, it will not have:
(1) Sold, encumbered, assigned let lapsed or transferred
any of its material assets, including without limitation the Intellectual
Property, the License Agreement or any other material asset;
(2) Amended or terminated the License Agreement or other
material agreement or done any act or omitted to do any act which would cause
the breach of the License Agreement or any other material agreement;
(3) Suffered any damage, destruction or loss whether or not
in control of AGTI;
(4) Made any commitments or agreements for capital
expenditures or otherwise;
(5) Entered into any transaction or made any commitment not
disclosed to CYDY;
(6) Incurred any material obligation or liability for
borrowed money;
Page 5 of 17
(7) Done or omitted to do any act, or suffered any other
event of any character, which is reasonable to expect, would adversely affect
the future condition (financial or otherwise), assets or liabilities or business
of AGTI; or
(8) Taken any action, which could reasonably be foreseen to
make any of the representations or warranties made by AGTI or UTEK untrue as of
the date of this Agreement or as of the Closing Date.
(n) Material Agreements. Exhibit A attached contains a true
and complete list of all contemplated and executed agreements between AGTI and a
third party. A complete and accurate copies of all material agreements,
contracts and commitments of the following types, whether written or oral, to
which it is a party or is bound (Contracts), has been provided to CYDY. Such
executed Contracts are, and such contemplated Contracts will be, at the Closing
Date, in full force and effect without modifications or amendment and constitute
the legally valid and binding obligations of AGTI in accordance with their
respective terms and will continue to be valid and enforceable following the
Acquisition. AGTI is not, and will not be at the Closing Date, in default of any
of the Contracts. In addition:
(1) There are no outstanding unpaid promissory notes,
mortgages, indentures, deed of trust, security agreements and other agreements
and instruments relating to the borrowing of money by or any extension of credit
to AGTI; and
(2) There are no outstanding operating agreements, lease
agreements or similar agreements by which AGTI is bound; and
(3) The complete final draft of the License Agreement and
Consulting Agreement have been provided to CYDY; and
(4) Except as set forth in (3) above, there are no
outstanding licenses to or from others of any Intellectual Property and trade
names; and
(5) There are no outstanding agreements or commitments to
sell, lease or otherwise dispose of any of AGTl's property; and
(6) There are no breaches of any agreement to which AGTI is
a party.
(o) Compliance with Laws. AGTI is in compliance with all
applicable laws, rules, regulations and orders promulgated by any federal, state
or local government body or agency relating to its business and operations.
(p) Litigation. There is no suit, action or any arbitration,
administrative, legal or other proceeding of any kind or character, or any
governmental investigation pending or to the best knowledge of AGTI or UTEK,
threatened against AGTI, the Technology, or License Agreement, affecting its
assets or business (financial or otherwise), and neither AGTI nor UTEK is in
violation of or in default with respect to any judgment, order, decree or other
finding of any court or government authority relating to the assets, business or
properties of AGTI or the transactions contemplated hereby. There are no pending
or threatened actions or proceedings before any court, arbitrator or
administrative agency, which would, if adversely determined, individually or in
the aggregate, materially and adversely affect the assets or business of AGTI or
the transactions contemplated hereby.
(q) Employees. AGTI has no and never had any employees. AGTI is
not a party to or bound by any employment agreement or any collective bargaining
agreement with respect to any employees. AGTI is not in violation of any law,
rule or regulation relating to employment of employees.
Page 6 of 17
(r) Neither AGTI nor UTEK has any knowledge of any existing or
threatened occurrence, action or development that could cause a material adverse
effect on AGTI or its business, assets or condition (financial or otherwise) or
prospects.
(s) Employee Benefit Plans. There are no and have never been any
employee benefit plans, and there are no commitments to create any, including
without limitation as such term is defined in the Employee Retirement Income
Security Act of 1974, as amended, in effect, and there are no outstanding or
un-funded liabilities nor will the execution of this Agreement and the actions
contemplated in this Agreement result in any obligation or liability to any
present or former employee.
(t) Books and Records. The books and records of AGTI are complete
and accurate in all material respects, fairly present its business and
operations, have been maintained in accordance with good business practices, and
applicable legal requirements, and accurately reflect in all material respects
its business, financial condition and liabilities.
(u) No Broker's Fees. Neither UTEK nor AGTI has incurred any
investment banking, advisory or other similar fees or obligations in connection
with this Agreement or the transactions contemplated by this Agreement.
(v) Full Disclosure. All representations or warranties of UTEK and
AGTI are true, correct and complete in all material respects to the best of
UTEK's and AGTl's knowledge on the date of this Agreement and shall be true,
correct and complete in all material respects as of the Closing Date as if they
were made on such date. No statement made by them in this Agreement or in the
exhibits and schedules to this Agreement or any document delivered by them or on
their behalf pursuant to this Agreement contains an untrue statement of material
fact or omits to state all material facts necessary to make the statements in
this Agreement not misleading in any material respect in light of the
circumstances in which they were made.
2.02 Representations and Warranties of CYDY. CYDY represents and warrants
to UTEK and AGTI that the facts set forth below are true and correct.
(a) Organization. CYDY is a corporation duly organized, validly
existing and in good standing under the laws of Colorado, is qualified to do
business as a foreign corporation in other jurisdictions in which the conduct of
its business or the ownership of its properties require such qualification, and
have all requisite power and authority to conduct its business and operate its
properties.
(b) Authorization. The execution of this Agreement and the
consummation of the Acquisition and the other transactions contemplated by this
Agreement have been duly authorized by the board of directors of CYDY; no other
corporate action on CYDY's part is necessary in order to execute, deliver,
consummate and perform its obligations hereunder; and it has all requisite
corporate and other authority to execute and deliver this Agreement and
consummate the transactions contemplated by this Agreement.
(c) Binding Effect. The execution, delivery, performance and
consummation of the Acquisition and the transactions contemplated by this
Agreement will not violate any obligation to which CYDY is a party and will not
create a default hereunder, and this Agreement constitutes a legal, valid and
binding obligation of CYDY, enforceable in accordance with its terms, except as
the enforcement may be limited by bankruptcy, insolvency, moratorium, or similar
laws affecting creditor's rights generally and by the availability of injunctive
relief, specific performance or other equitable remedies.
(d) Litigation Relating to this Agreement. There are no suits,
actions or proceedings pending or to its knowledge threatened which seek to
enjoin the Acquisition or the transactions contemplated by this Agreement or
which, if adversely decided, would have a materially adverse effect on its
business, results of operations, assets, prospects or the results of its
operations of CYDY.
Page 7 of 17
(e) No Conflicting Agreements. Neither the execution and delivery
of this Agreement nor the fulfillment of or compliance by CYDY with the terms or
provisions of this Agreement will result in a breach of the terms, conditions or
provisions of, or constitute default under, or result in a violation of, the
corporate charter or bylaws, or any agreement, contract, instrument, order,
judgment or decree to which it is a party or by which it or any of its assets
are bound, or violate any provision of any applicable law, rule or regulation or
any order, decree, writ or injunction of any court or governmental entity which
materially affects its assets or business.
(f) Consents. Assuming the correctness of UTEK's and AGTl's
representations, no consent from or approval of any court, governmental entity
or any other person is necessary in connection with its execution and delivery
of this Agreement; and the consummation of the transactions contemplated by this
Agreement will not require the approval of any entity or person in order to
prevent the termination of any material right, privilege, license or agreement
relating to CYDY or its assets or business.
(g) Financial Statements. The audited financial statements of CYDY
attached as Exhibit C present fairly its financial position and the results of
its operations on the dates and for the periods shown on such statements;
provided, however, that interim financial statements are subject to customary
year-end adjustments and accruals that, in the aggregate, will not have a
material adverse effect on the overall financial condition or results of its
operations. CYDY has not engaged in any business not reflected in its financial
statements. There have been no material adverse changes in the nature of its
business, prospects, the value of assets or the financial condition since the
date of its financial statements. There are no outstanding obligations or
liabilities of CYDY except as specifically set forth in the CYDY financial
statements.
(h) Full Disclosure. All representations or warranties of CYDY are
true, correct and complete in all material respects on the date of this
Agreement and shall be true, correct and complete in all material respects as of
the Closing Date as if they were made on such date. No statement made by it in
this Agreement or in the exhibits to this Agreement or any document delivered by
it or on its behalf pursuant to this Agreement contains an untrue statement of
material fact or omits to state all material facts necessary to make the
statements in this Agreement not misleading in any material respect in light of
the circumstances in which they were made.
(i) Compliance with Laws. CYDY is in compliance with all
applicable laws, rules, regulations and orders promulgated by any federal, state
or local government body or agency relating to its business and operations.
(j) Litigation. There is no suit, action or any arbitration,
administrative, legal or other proceeding of any kind or character, or any
governmental investigation pending or, to the best knowledge of CYDY, threatened
against CYDY materially affecting its assets or business (financial or
otherwise), and CYDY is not in violation of or in default with respect to any
judgment, order, decree or other finding of any court or government authority.
There are no pending or, to the knowledge of CYDY, threatened actions or
proceedings before any court, arbitrator or administrative agency, which would,
if adversely determined, individually or in the aggregate, materially and
adversely affect its assets or business. CYDY has no knowledge of any existing
or threatened occurrence, action or development that could cause a material
adverse affect on CYDY or its business, assets or condition (financial or
otherwise) or prospects.
(k) Development. CYDY agrees and warrants that it has the
expertise necessary to and has had the opportunity to independently evaluate the
inventions of the Licensed Patents and develop same for the market. CYDY further
agrees that it will provide UTEK with copies of progress reports made to the
university as required under the subject license agreement on a quarterly basis.
(l) Investment Company. CYDY is not an investment company, either
registered or unregistered.
Page 8 of 17
2.03 Investment Representations of UTEK. UTEK represents and warrants to
CYDY that:
(a) General. It has such knowledge and experience in financial and
business matters as to be capable of evaluating the risks and merits of an
investment in CYDY Shares pursuant to the Acquisition. It is able to bear the
economic risk of the investment in CYDY Shares, including the risk of a total
loss of the investment in CYDY Shares. The acquisition of CYDY Shares is for its
own account and is for investment and not with a view to any distribution of
such shares. Except a permitted by law, it has no present intention of selling,
transferring or otherwise disposing in any way of all or any portion of the
shares at the present time. All information that it has supplied to CYDY is true
and correct. It has conducted all investigations and due diligence concerning
CYDY to evaluate the risks inherent in accepting and holding the shares which it
deems appropriate, and it has found all such information obtained fully
acceptable. It has had an opportunity to ask questions of the officers and
directors of CYDY concerning CYDY Shares and the business and financial
condition of and prospects for CYDY, and the officers and directors of CYDY have
adequately answered all questions asked and made all relevant information
available to them. UTEK is an "accredited investor," as the term is defined in
Regulation D, promulgated under the Securities Act of 1933, amended, and the
rules and regulations thereunder.
ARTICLE 3
TRANSACTIONS PRIOR TO CLOSING
3.01. Corporate Approvals. Prior to Closing Date, each of the parties
shall submit this Agreement to its board of directors and, if necessary, its
respective shareholders and obtain approval of this Agreement. Copies of
corporate actions taken shall be provided to each party.
3.02 Access to Information. Each party agrees to permit, upon reasonable
notice, the attorneys, accountants, and other representatives of the other
parties reasonable access during normal business hours to its properties and its
books and records to make reasonable investigations with respect to its affairs,
and to make its officers and employees available to answer questions and provide
additional information as reasonably requested.
3.03 Expenses. Each party agrees to bear its own expenses in connection
with the negotiation and consummation of the Acquisition and the transactions
contemplated by this Agreement.
3.04 Covenants. Except with the prior written approval of CYDY or of AGTI
or UTEK, as the case may be, each party agrees that it will:
(a) Use its good faith efforts to obtain all requisite licenses,
permits, consents, approvals and authorizations necessary in order to consummate
the Acquisition; and
(b) Notify the other parties upon the occurrence of any event
which would have a materially adverse effect upon the Acquisition or the
transactions contemplated by this Agreement or upon the business, assets or
results of operations; and
(c) Not modify its corporate structure, except, upon prior written
notice to the other parties, as necessary or advisable in order to consummate
the Acquisition and the transactions contemplated by this Agreement.
Page 9 of 17
ARTICLE 4
CONDITIONS PRECEDENT
The obligation of the parties to consummate the Acquisition and the
transactions contemplated by this Agreement are subject to the following
conditions that may be waived, to the extent permitted by law:
4.01. Each party must obtain the approval of its board of directors and
such approval shall not have been rescinded or restricted.
4.02. Each party shall obtain all requisite licenses, permits, consents,
authorizations and approvals required to complete the Acquisition and the
transactions contemplated by this Agreement.
4.03. There shall be no claim or litigation instituted or threatened in
writing by any person or government authority seeking to restrain or prohibit
any of the contemplated transactions contemplated by this Agreement or challenge
the right, title and interest of UTEK in the AGTI Shares, AGTI in the License
Agreement, or the right of AGTI or UTEK to consummate the Acquisition
contemplated hereunder.
4.04. The representations and warranties of the parties shall be true and
correct in all material respects at the Effective Date.
4.05. The Technology and Intellectual Property shall have been prosecuted
in good faith with reasonable diligence.
4.06. The License Agreement and Consulting Agreement shall have been
executed and delivered by all parties thereto and, to the best knowledge of UTEK
and AGTI, the License Agreement and Consulting Agreement shall be valid and in
full force and effect without any default under such agreement.
4.07. CYDY shall have received, at or within 5 days before the Closing
Date, each of the following:
(a) the stock certificates representing the AGTI Shares, duly
endorsed (or accompanied by duly executed stock powers) by UTEK for
cancellation;
(b) all documentation relating to AGTl's business, all in form and
substance satisfactory to CYDY;
(c) such agreements, files and other data and documents pertaining
to AGTI's business as CYDY may reasonably request;
(d) copies of the general ledgers and books of account of AGTI,
and all federal, state and local income, franchise, property and other tax
returns filed by AGTI since the inception of AGTI;
(e) certificates of (i) the Secretary of State of the State of
Florida as to the legal existence and good standing, as applicable (including
tax), of AGTI in Florida;
(f) the original corporate minute books of AGTI, including the
articles of incorporation and bylaws of AGTI, and all other documents filed in
this Agreement;
(g) all consents, assignments or related documents of conveyance
to give CYDY the benefit of the transactions contemplated hereunder;
(h) such documents as may be needed to accomplish the Closing
under the corporate laws of the states of incorporation of CYDY and AGTI, and
Page 10 of 17
(i) such other documents, instruments or certificates as CYDY, or
its counsel may reasonably request.
4.08. CYDY shall have completed its due diligence investigation of AGTI
to CYDY's satisfaction in its sole discretion.
4.09. CYDY shall receive the resignations of each director and officer of
AGTI effective the Closing Date.
ARTICLE 5
INDEMNIFICATION AND LIABILITY LIMITATION
5.01. Survival of Representations and Warranties.
(a) The representations and warranties made by UTEK and AGTI shall
survive for a period of 1 year after the Closing Date, and thereafter all such
representation and warranties shall be extinguished, except with respect to
claims then pending for which specific notice has been given during such 1-year
period.
(b) The representations and warranties made by CYDY shall survive
for a period of 1 year after the Closing Date, and thereafter all such
representations and warranties shall be extinguished, except with respect to
claims then pending for which specific notice has been given during such 1-year
period.
5.02 Limitations on Liability. CYDY agrees that UTEK shall not be liable
under this agreement to CYDY or their respective successor's, assigns or
affiliates except where damages result directly from the negligence or willful
misconduct of UTEK or its employees. In no event shall UTEK's liability exceed
the total amount of the fees paid to UTEK under this agreement, nor shall UTEK
be liable for incidental or consequential damages of any kind. CYDY shall
indemnify UTEK, and hold UTEK harmless against any and all claims by third
parties for losses, damages or liabilities, including reasonable attorneys fees
and expenses ("Losses"), arising in any manner out of or in connection with the
rendering of services by UTEK under this Agreement, unless it is finally
judicially determined that such Losses resulted from the negligence or willful
misconduct of UTEK. The terms of this paragraph shall survive the termination of
this agreement and shall apply to any controlling person, director, officer,
employee or affiliate of UTEK.
5.03 Indemnification. CYDY agrees to indemnify and hold harmless UTEK and
its subsidiaries and affiliates and each of its and their officers, directors,
principals, shareholders, agents, independent contactors and employees
(collectively "Indemnified Persons") from and against any and all claims,
liabilities, damages, obligations, costs and expenses (including reasonable
attorneys' fees and expenses and costs of investigation) arising out of or
relating to matters or arising from this Agreement, except to the extent that
any such claim, liability, obligation, damage, cost or expense shall have been
determined by final non-appealable order of a court of competent jurisdiction to
have resulted from the negligence or willful misconduct of the Indemnified
Person or Persons in respect of whom such liability is asserted.
(a) Limitation of Liability. CYDY agrees that no Indemnified
Person shall have any liability as a result of the execution and delivery of
this Agreement, or other matters relating to or arising from this Agreement,
other than liabilities that shall have been determined by final non-appealable
order of a court of competent jurisdiction to have resulted from the gross
negligence or willful misconduct of the Indemnified Person or Persons in respect
of whom such liability is asserted. Without limiting the generality of the
foregoing, in no event shall any Indemnified Person be liable for consequential,
indirect or punitive damages, damages for lost profits or opportunities or other
like damages or claims of any kind. In no event shall UTEK's liability exceed
the total amount of the fees paid to UTEK under this Agreement.
Page 11 of 17
ARTICLE 6
REMEDIES
6.01 Specific Performance. Each party's obligations under this Agreement
are unique. If any party should default in its obligations under this Agreement,
the parties each acknowledge that it would be extremely impracticable to measure
the resulting damages. Accordingly, the non-defaulting party, in addition to any
other available rights or remedies, may xxx in equity for specific performance,
and the parties each expressly waive the defense that a remedy in damages will
be adequate.
6.02 Costs. If any legal action or any arbitration or other proceeding is
brought for the enforcement of this Agreement or because of an alleged dispute,
breach, default, or misrepresentation in connection with any of the provisions
of this Agreement, the successful or prevailing party or parties shall be
entitled to recover reasonable attorneys' fees and other costs incurred in that
action or proceeding, in addition to any other relief to which it or they may be
entitled.
ARTICLE 7
ARBITRATION
In the event a dispute arises with respect to the interpretation or
effect of this Agreement or concerning the rights or obligations of the parties
to this Agreement, the parties agree to negotiate in good faith with reasonable
diligence in an effort to resolve the dispute in a mutually acceptable manner.
Failing to reach a resolution of this Agreement, either party shall have the
right to submit the dispute to be settled by arbitration under the Commercial
Rules of Arbitration of the American Arbitration Association. The parties agree
that, unless the parties mutually agree to the contrary such arbitration shall
be conducted in Los Angeles, California. The cost of arbitration shall be borne
by the party against whom the award is rendered or, if in the interest of
fairness, as allocated in accordance with the judgment of the arbitrators. All
awards in arbitration made in good faith and not infected with fraud or other
misconduct shall be final and binding. The arbitrators shall be selected as
follows: one by CYDY, one by UTEK and a third by the two selected arbitrators.
The third arbitrator shall be the chairman of the panel.
ARTICLE 8
MISCELLANEOUS
8.01. No party may assign this Agreement or any right or obligation of it
hereunder without the prior written consent of the other parties to this
Agreement. No permitted assignment shall relieve a party of its obligations
under this Agreement without the separate written consent of the other parties.
8.02. This Agreement shall be binding upon and inure to the benefit of
the parties and their respective permitted successors and assigns.
8.03. Each party agrees that it will comply with all applicable laws,
rules and regulations in the execution and performance of its obligations under
this Agreement.
8.04. This Agreement shall be governed by and construct in accordance
with the laws of the State of Delaware without regard to principles of conflicts
of law.
8.05. This document constitutes a complete and entire agreement among the
parties with reference to the subject matters set forth in this Agreement. No
statement or agreement, oral or written, made prior to or at the execution of
this Agreement and no prior course of dealing or practice by either party shall
vary or modify the terms set forth in this Agreement without the prior consent
of the other parties to this Agreement. This Agreement may be amended only by a
written document signed by the parties.
8.06. Notices or other communications required to be made in connection
with this Agreement shall be sent by U.S. mail, certified, return receipt
Page 12 of 17
requested, personally delivered or sent by express delivery service and
delivered to the parties at the addresses set forth below or at such other
address as may be changed from time to time by giving written notice to the
other parties.
8.07. The invalidity or unenforceability of any provision of this
Agreement shall not affect the validity or enforceability of any other provision
of this Agreement.
8.08. This Agreement may be executed in multiple counterparts, each of
which shall constitute one and a single Agreement.
8.09 Any facsimile signature of any part to this Agreement or to any
other Agreement or document executed in connection of this Agreement should
constitute a legal, valid and binding execution by such parties.
CYTODYN, INC. ADVANCED GENETIC TECHNOLOGIES, INC.
By: /s/ Xxxxx X. Xxxxx By:
--------------------------- ---------------------------
Xxxxx X. Xxxxx, Xxxx X. Xxxxxxx
CEO President
Address: Address:
00 X. Xxxxxx Xxxxxx 0000 X. Xxxx Xxxxxx
Xxxxx X Xxxxx, Xxxxxxx 00000
Xxxxx Xx XX 00000
Date: January 25, 2007 Date:
------------------------- -------------------------
UTEK CORPORATION COMPLIANCE OFFICER
By: By:
--------------------------- ---------------------------
Xxxxxxx Xxxxxxxxx
Chief Operating Officer
Date:
Address: -------------------------
0000 X. Xxxx Xxxxxx
Xxxxx, Xxxxxxx 00000
Date:
-------------------------
Page 13 of 17
EXHIBIT A
Outstanding Agreements
1. Exclusive License Agreement from the CBR Institute for Biomedical
Research, affiliated with the Harvard Medical School, attached hereto and
embodied herein by reference as if fully set forth in this Agreement.
Page 14 of 17
EXHIBIT B
ASSETS OF ADVANCED GENETIC TECHNOLOGIES, Inc.
Financial Statements as of
January 26, 2006
When delivered to CYDY by Utek, AGTI shall have the following assets:
1) The exclusive license agreement referenced in Appendix A, with the first
seven (7) year's fees fully paid,
2) $100,000 in cash against which there is no obligation or liability over
the first seven (7) years as shown in the License Agreement and Financial
Statements as of January 26, 2007 attached herein
Page 15 of 17
EXHIBIT C
CytoDyn, Inc.
FORM 10-QSB or Audited Financials
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Including Audited Financial Statements
For the fiscal quarter ended September 30, 2006
Page 16 of 17
EXHIBIT D
Provided By CytoDyn, Inc.:
1) Certificate of Designation of the Rights and Preferences of Convertible
Preferred Stock
2) Board of Director's Authorization and Certificate of Acquisition
3) Irrevocable Transfer Agent Instructions
Page 17 of 17
